Marie A. Chisholm-Burns, PharmD, PhD, MPH, MBA, FCCP, FASHP, FAST, executive vice president and provost at Oregon Health and Science University, is receiving the award, which is presented to individuals who demonstrate excellence in pharmacy practice leadership.
Over the decades, the American Society of Health-System Pharmacists (ASHP) has been there during the career of Marie A. Chisholm-Burns, PharmD, PhD, MPH, MBA, FCCP, FASHP, FAST.
At this year’s ASHP Midyear Clinical Meeting & Exposition, Chisholm-Burns, executive vice president and provost at Oregon Health and Science University, will be receiving the ASHP Board of Directors’ Distinguished Leadership Award for her work in pharmacy practice leadership and academic pharmacy.
Transcript
What is the ASHP Board of Directors’ Distinguished Leadership Award, and what work have you done leading to you receiving this award at the 2023 ASHP Midyear Clinical Meeting & Exposition?
First, I want to thank ASHP Board of Directors for selecting me for the Distinguished Leadership Award. The award, to my understanding, is for individuals who have excellence in pharmacy practice leadership. I've done several things not only in pharmacy practice, but also in pharmacy practice leadership, including academic pharmacy, so I'm just honored.
ASHP is an organization that really means a lot to me. It's probably been there since the beginning with [my] residency training. I don't want to age myself here, but it's been decades that we have been friends and on this journey together. I also had the honor of being the founding chair, and now the past chair of the ASHP's new Section of Pharmacy Educators. And so that means a lot to me. It means a lot that ASHP has asked me to be involved in several things over the years.
So, that's a little bit about the award. I'm looking forward to receiving the award. My husband, John, is going to be there. And I'm just looking forward to seeing people again. I’m very excited about many things. Life is good.
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
FLT3 Inhibitor Gilteritinib May Also Be Effective as ALK Inhibitor in AML
October 20th 2024The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be used as an anaplastic lymphoma kinase (ALK) inhibitor.
Read More